Document Type : Research Articles
Department ofClinical and Chemical pathology, National Cancer Institute, Cairo University, Egypt.
Departments of Biochemistry, Faculty of Pharmacy (Girls), AL-Azhar University, Egypt.
Department of Oncologic Pathology, National Cancer Institute, Cairo University, Egypt.
Department of Medical Oncology, National Cancer Institute, Cairo University, Egypt.
Department of Chemistry, Faculty of Science ,HelwanUniveristy, Cairo, Egypt.
Objective: To determine the frequency and prognostic significance of vitamin D deficiency in Egyptian women
with breast cancer (BC). Methods: This prospective study included 50 women with primary invasive, non-metastatic
BC. The serum level of 25-hydroxy vitamin D [25(OH)D was measured by ELISA at diagnosis, before any cancer
treatment. Vitamin D deficiency was defined as 25(OH) Dmonths (range: 18-48). Results: The median level of 25(OH)D was 29.0 ng/mL (range: 10.0-55.0 ng/mL). Fifteen
patients (30%) had vitamin D deficiency, which was positively associated with larger tumor size (p < 0.001), higher
grade (p = 0.014), advanced stage (p = 0.001), lymph node positivity (p = 0.012), and HER2/neureceptor expression
(p = 0.002). It was also linked with worse overall survival (OS) and disease free survival (DFS) (p = 0.026, and
p = 0.004, respectively). On multivariate analysis, DFS was independently affected by vitamin D deficiency with
an HR of 2.8 (95% CI: 1.6-7.0, p = 0.022) and advanced stage, i.e. stage II had worse survival compared to stage I with
an HR of 4.8 (95%CI: 1.1-21.7, p = 0.042). Conclusion: Vitamin D deficiency had a negative effect on overall and
disease-free survival in our breast cancer cases, being related to tumor size, stage, grade, nodal status and HER2/neu